Juliana Hofstatter Azambuja

10PUBLICATIONS
5CO-AUTHORS
Tumour immunologyMechanobiologyMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 10, 2024
MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression.

Juliana Hofstätter Azambuja, Saigopalakrishna S Yerneni, Lisa M Maurer

|Jan 13, 2021
Artesunate Switches Monocytes to an Inflammatory Phenotype with the Ability to Kill Leukemic Cells.

Rubia Isler Mancuso, Sara Teresinha Olalla Saad, Juliana Hofstätter Azambuja

|Jun 06, 2020
Arginase-1+ Exosomes from Reprogrammed Macrophages Promote Glioblastoma Progression.

Juliana H Azambuja, Nils Ludwig, Saigopalakrishna S Yerneni

|May 18, 2020
CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.

J H Azambuja, R S Schuh, L R Michels

|May 01, 2020
Blockade of CD73 delays glioblastoma growth by modulating the immune environment.

J H Azambuja, R S Schuh, L R Michels

|Dec 19, 2019
Development and characterization of CD73-siRNA-loaded nanoemulsion: effect on C6 glioma cells and primary astrocytes.

Fernanda C Teixeira, Fernanda Bruxel, Juliana H Azambuja

Pageof 2